Search

Gossamer Bio Inc

Gesloten

SectorGezondheidszorg

10.61 7,478.57

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.46

Max

10.74

Belangrijke statistieken

By Trading Economics

Inkomsten

64M

17M

Verkoop

-7.7M

9.2M

EPS

-0.2

Winstmarge

182.94

Werknemers

161

EBITDA

-28M

-71M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-90.03% downside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-391K

86M

Vorige openingsprijs

-7467.96

Vorige sluitingsprijs

10.61

Nieuwssentiment

By Acuity

79%

21%

314 / 339 Rangschikking in Healthcare

Gossamer Bio Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 sep 2026, 23:01 UTC

Gossamer Bio Inc. shares are higher in after-hours trading, reflecting a notable increase since Friday's close amid positive market sentiment following a narrower U.S. budget deficit.

10 sep 2026, 23:31 UTC

Event

Gossamer Bio Inc. shares rose in after-market trading following a 1-for-80 reverse stock split, advancing from earlier levels despite broader market dynamics.

9 sep 2026, 23:53 UTC

Gossamer Bio Inc. shares are lower in after-market hours following a significant decline since Wednesday's close, despite an earlier attempt to recover.

4 sep 2026, 19:26 UTC

Gossamer Bio shares are lower today amid increased selling pressure on risk assets, influenced by strong jobs data and rising interest rate expectations.

3 sep 2026, 23:26 UTC

Gossamer Bio Inc shares are lower in after-market hours, with no specific news identified for the decline. Major indices rose amid reduced interest rate hike expectations.

2 sep 2026, 23:06 UTC

Gossamer Bio Inc. shares are higher in after-market trading, remaining above their 20-day moving average and within the one-month trading range.

1 sep 2026, 23:06 UTC

Gossamer Bio Inc. shares declined in after-market trading, influenced by rising oil prices and inflation concerns amid a broader performance below the 20-day moving average.

31 aug 2026, 20:07 UTC

Gossamer Bio Inc is higher today amid broader market reactions to potential Federal Reserve interest rate hikes following remarks from Warsh at the Jackson Hole symposium.

28 aug 2026, 23:06 UTC

Gossamer Bio Inc. shares are higher in after-market trading, reflecting positive momentum since Friday's close amid broader market volatility.

27 aug 2026, 23:01 UTC

News

Gossamer Bio announced a private placement that could yield up to $250 million, with an initial $25 million expected upfront. Shares are roughly flat in after-market hours.

26 aug 2026, 23:01 UTC

Gossamer Bio Inc is higher in after-market trading, reflecting broader market gains amid positive economic data on personal consumption and durable goods orders.

25 aug 2026, 23:01 UTC

Gossamer Bio shares were lower in after-market hours, with no specific news identified. The broader market retreated after an initial advance amid falling crude oil prices.

24 aug 2026, 23:01 UTC

Gossamer Bio Inc. shares are lower in after-market trading amid notable volatility and ongoing geopolitical tensions involving the U.S. and Iran.

22 aug 2026, 00:01 UTC

Gossamer Bio Inc. shares advanced in after-market trading, recovering from earlier lows amid broader market gains despite no specific company news identified.

21 aug 2026, 23:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, following broader market gains despite earlier lower trading. No specific news was identified for the move.

20 aug 2026, 23:01 UTC

Gossamer Bio shares are lower in after-market trading, reflecting broader market pressures following Walmart's disappointing sales growth and guidance.

19 aug 2026, 23:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, following a notable peak earlier in the session. The stock remains below its 20-day moving average.

18 aug 2026, 23:01 UTC

Gossamer Bio Inc shares rose in after-market trading following Tuesday's close, though no specific news was identified to explain the movement.

17 aug 2026, 23:31 UTC

Gossamer Bio Inc shares are sharply higher in after-market trading, rising significantly despite being below its 20-day moving average and recent declines.

15 aug 2026, 00:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, though no specific news explains the movement. The price remains below its 20-day moving average.

14 aug 2026, 22:51 UTC

Gossamer Bio Inc. shares are higher in after-market hours, despite disappointing U.S. retail sales data influencing broader market sentiment.

13 aug 2026, 23:01 UTC

News

Gossamer Bio reported second-quarter net income of $16.9 million and plans to submit a New Drug Application for seralutinib in September 2026. Shares are higher in after-market trading.

12 aug 2026, 23:01 UTC

Gossamer Bio Inc. shares advanced in after-market trading, continuing a strong performance since July 13, despite earlier fluctuations during the session.

11 aug 2026, 23:11 UTC

No specific news was identified for Gossamer Bio Inc. in after-market trading, with shares effectively unchanged since Tuesday's close.

10 aug 2026, 23:01 UTC

Gossamer Bio Inc. shares are higher in after-hours trading, reflecting strong performance and positioning above the 20-day moving average. No specific news was identified.

7 aug 2026, 19:56 UTC

Gossamer Bio Inc shares are higher today amid a weaker jobs report, easing interest rate hike concerns and shifting market sentiment towards a dovish outlook.

6 aug 2026, 23:12 UTC

Gossamer Bio Inc. shares are effectively unchanged in after-market trading, remaining flat within a narrow band. The stock is above its 20-day moving average.

5 aug 2026, 23:36 UTC

Gossamer Bio Inc shares are higher in after-market trading, despite no specific news. The stock is also above its 20-day moving average.

4 aug 2026, 23:01 UTC

Gossamer Bio shares declined after-market, reflecting broader market trends amid falling crude oil prices. Volatility was noted with fluctuations in trading.

3 aug 2026, 23:06 UTC

Gossamer Bio Inc. shares remained roughly flat in after-market hours, with no specific news identified. Broader market sentiment improved following strong manufacturing data.

Peer Vergelijking

Prijswijziging

Gossamer Bio Inc Prognose

Koersdoel

By TipRanks

-90.03% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 1.07 USD  -90.03%

Hoogste 2 USD

Laagste 0.28 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Gossamer Bio Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

2

Buy

2

Hold

1

Sell

Sentiment

By Acuity

314 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

$

Over Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
help-icon Live chat